MA55007B1 - Composition liquide de clotrimazole emballée à dose unique - Google Patents

Composition liquide de clotrimazole emballée à dose unique

Info

Publication number
MA55007B1
MA55007B1 MA55007A MA55007A MA55007B1 MA 55007 B1 MA55007 B1 MA 55007B1 MA 55007 A MA55007 A MA 55007A MA 55007 A MA55007 A MA 55007A MA 55007 B1 MA55007 B1 MA 55007B1
Authority
MA
Morocco
Prior art keywords
composition
clotrimazole
liquid composition
packaged
single dose
Prior art date
Application number
MA55007A
Other languages
English (en)
Other versions
MA55007A (fr
Inventor
Javier SANAGUSTÍN AQUILUÉ
Maria Mar TERRAZ MENDOZA
Adolfo TÉLLEZ MOLINA
María Isabel DELGADO GAÑÁN
Original Assignee
Laboratorios Salvat, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat, S.A. filed Critical Laboratorios Salvat, S.A.
Publication of MA55007A publication Critical patent/MA55007A/fr
Publication of MA55007B1 publication Critical patent/MA55007B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une unité d'emballage à dose unique, en l'occurrence, un contenant faisant appel à la technologie blow-fill-seal (BFS), qui comprend une solution de composition liquide vétérinaire ou pharmaceutique stérile. a) La composition comprend une quantité thérapeutiquement efficace de clotrimazole ou d'un sel de celui-ci acceptable sur le plan pharmaceutique ou vétérinaire, ainsi qu'un ou plusieurs véhicules ou excipients acceptables sur le plan pharmaceutique ou vétérinaire et b) le récipient a un volume de 0,05 à 8 mL, à condition que la teneur en eau de la composition soit inférieure ou égale à 4 % en poids par rapport au poids total de la composition. L'invention concerne également un emballage secondaire comprenant une ou plusieurs unités d'emballage à dose unique.
MA55007A 2019-02-19 2020-02-18 Composition liquide de clotrimazole emballée à dose unique MA55007B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382120 2019-02-19
EP20704341.5A EP3927310B1 (fr) 2019-02-19 2020-02-18 Composition liquide de clotrimazole emballée à dose unique
PCT/EP2020/054250 WO2020169611A1 (fr) 2019-02-19 2020-02-18 Composition liquide de clotrimazole dans un emballage à dose unique

Publications (2)

Publication Number Publication Date
MA55007A MA55007A (fr) 2021-12-29
MA55007B1 true MA55007B1 (fr) 2024-06-28

Family

ID=65766941

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55007A MA55007B1 (fr) 2019-02-19 2020-02-18 Composition liquide de clotrimazole emballée à dose unique

Country Status (28)

Country Link
US (1) US12246006B2 (fr)
EP (1) EP3927310B1 (fr)
JP (1) JP7514844B2 (fr)
KR (1) KR102940238B1 (fr)
CN (1) CN113423382B (fr)
AU (1) AU2020225663B2 (fr)
CA (1) CA3127151A1 (fr)
CL (1) CL2021001882A1 (fr)
CO (1) CO2021010326A2 (fr)
CR (1) CR20210473A (fr)
DO (1) DOP2021000169A (fr)
ES (1) ES2980452T3 (fr)
HR (1) HRP20240866T1 (fr)
HU (1) HUE067872T2 (fr)
IL (1) IL284858B2 (fr)
MA (1) MA55007B1 (fr)
MD (1) MD3927310T2 (fr)
MX (1) MX2021008803A (fr)
PE (1) PE20211892A1 (fr)
PH (1) PH12021551694A1 (fr)
PL (1) PL3927310T3 (fr)
RS (1) RS65657B1 (fr)
SA (1) SA521422538B1 (fr)
SG (1) SG11202107773RA (fr)
SM (1) SMT202400262T1 (fr)
TW (1) TWI834808B (fr)
WO (1) WO2020169611A1 (fr)
ZA (1) ZA202105236B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017187262A1 (fr) 2016-04-25 2017-11-02 Marc Andrew Koska Système d'administration de médicament
EP3710086A4 (fr) 2017-11-17 2021-11-17 Koska Family Limited Systèmes et procédés pour distributeurs de fluide
US12544511B2 (en) 2018-06-20 2026-02-10 Koska Family Limited Systems and methods for pre-filled dual-chamber medical agent delivery
WO2021207282A2 (fr) 2020-04-07 2021-10-14 Combangio, Inc. Sécrétome dérivé de cellules souches mésenchymateuses lyophilisées et utilisations associées
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
JP2025530090A (ja) * 2022-09-07 2025-09-11 コンバンジョ・インコーポレイテッド 間葉系幹細胞由来セクレトームの調製及び精製方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598112A (en) 1979-01-17 1980-07-25 Sumitomo Chem Co Ltd Liquid medicine for external use
JP2555555B2 (ja) * 1991-07-03 1996-11-20 武田薬品工業株式会社 抗真菌性外用製剤
CA2563365A1 (fr) 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Systeme d'administration de medicament en doses unitaires multiples
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
EP1712220A1 (fr) * 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Composition d'aérosol pharmaceutique
KR20090100358A (ko) 2006-11-16 2009-09-23 이-테라퓨틱스 리미티드 스타필로로커스 감염의 치료를 위한 클로트리마졸
GB0700380D0 (en) 2007-01-09 2007-02-14 Breath Ltd Storage Of Ampoules
DE102007056462B4 (de) * 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
WO2011121604A2 (fr) * 2010-03-29 2011-10-06 Lincoln Pharmaceuticals Limited Formulation de pulvérisation vaginale liquide pour le traitement d'une infection vaginale fongique
ES2565353T3 (es) * 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
US8933112B2 (en) 2012-06-15 2015-01-13 Memphaceuticals, LLC Topical liquid to ameliorate pain and promote healing of burn-injured skin
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations

Also Published As

Publication number Publication date
IL284858B1 (en) 2025-06-01
EP3927310B1 (fr) 2024-04-10
CN113423382A (zh) 2021-09-21
EP3927310A1 (fr) 2021-12-29
JP2022520714A (ja) 2022-04-01
KR102940238B1 (ko) 2026-03-16
US12246006B2 (en) 2025-03-11
RS65657B1 (sr) 2024-07-31
DOP2021000169A (es) 2021-09-30
CR20210473A (es) 2021-10-08
AU2020225663A1 (en) 2021-08-12
ES2980452T3 (es) 2024-10-01
CN113423382B (zh) 2024-10-29
MX2021008803A (es) 2021-11-12
TWI834808B (zh) 2024-03-11
PL3927310T3 (pl) 2024-08-05
SG11202107773RA (en) 2021-08-30
MA55007A (fr) 2021-12-29
CL2021001882A1 (es) 2022-02-11
MD3927310T2 (ro) 2024-08-31
EP3927310C0 (fr) 2024-04-10
CA3127151A1 (fr) 2020-08-27
KR20210131313A (ko) 2021-11-02
WO2020169611A1 (fr) 2020-08-27
SMT202400262T1 (it) 2024-07-09
PH12021551694A1 (en) 2022-05-11
IL284858A (en) 2021-08-31
HRP20240866T1 (hr) 2024-10-11
PE20211892A1 (es) 2021-09-22
IL284858B2 (en) 2025-10-01
JP7514844B2 (ja) 2024-07-11
CO2021010326A2 (es) 2021-08-19
ZA202105236B (en) 2023-10-25
AU2020225663B2 (en) 2024-03-14
SA521422538B1 (ar) 2024-03-28
TW202045161A (zh) 2020-12-16
US20220133695A1 (en) 2022-05-05
HUE067872T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
MA55007B1 (fr) Composition liquide de clotrimazole emballée à dose unique
Hirschfeld et al. Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine
MA27804A1 (fr) Produit pharmaceutique stabilise
FI4101454T3 (fi) Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon
PE20021075A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
Qiu et al. Postpartum fluoxetine increased maternal inflammatory signalling and decreased tryptophan metabolism: Clues for efficacy
PE20242104A1 (es) Formulaciones y sistemas de erdafitinib para administracion intravesical
RU2008134707A (ru) Способы и композиции для лечения гипертиреоза у кошачьих
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
MX2021009084A (es) Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
Chitasombat et al. Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series
MX2025007032A (es) Composicion farmaceutica tipo colirio que contiene enavogliflozina
PE20030090A1 (es) Medicamento que contiene un efector del metabolismo de glutation
FR2456474A1 (fr) Agent d'entretien pouvant etre pulverise a partir d'un conteneur, et procede pour l'entretien d'instruments medicaux, notamment de dentisterie avec un tel agent
BE1002255A5 (fr) Medicaments.
CN1901928B (zh) 偏头痛药物
JP2023030691A (ja) 眼科組成物
HUP0004454A2 (hu) APO B szekréciós/MTP inhibitor hatású gyógyszerkészítmények
BE904717A (nl) Farmaceutisch preparaat.
WO2004082559A3 (fr) Dose unitaire de complement dietetique omega-3 liquide contenue dans un conditionnement par doses
US20080287543A1 (en) Pharmaceutical composition comprising 5-methyl-2 (2'-chloro-6'-fluoroanillino) phen ylacetic acid
FR3097849B1 (fr) Matériau pour emballage alimentaire et procédé de préparation
ES2107389B1 (es) Procedimiento para conservar en vacio plantas medicinales.
Cream et al. TINEA PEDIS (ATHLETE'S FOOT)
UA124257U (uk) Лікарський засіб у вигляді м'яких капсул для орального застосування, який містить симетикон